Algernon Pharmaceuticals (XCNQ:AGN) Cash-to-Debt

: No Debt ⁽¹⁾ (As of Nov. 2023)

View and export this data going back to 2016. Start your Free Trial

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Algernon Pharmaceuticals's cash to debt ratio for the quarter that ended in Nov. 2023 was No Debt ⁽¹⁾.

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, Algernon Pharmaceuticals could pay off its debt using the cash in hand for the quarter that ended in Nov. 2023.

(1) Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

The historical rank and industry rank for Algernon Pharmaceuticals's Cash-to-Debt or its related term are showing as below:

XCNQ:AGN' s Cash-to-Debt Range Over the Past 10 Years
Min: No Debt Med: No Debt Max: No Debt
Current: No Debt

During the past 9 years, Algernon Pharmaceuticals's highest Cash to Debt Ratio was No Debt. The lowest was No Debt. And the median was No Debt.

XCNQ:AGN's Cash-to-Debt is ranked better than
99.74% of 1539 companies
in the Biotechnology industry
Industry Median: 6.42 vs XCNQ:AGN: No Debt

Algernon Pharmaceuticals Cash-to-Debt Historical Data

The historical data trend for Algernon Pharmaceuticals's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Algernon Pharmaceuticals Annual Data

Trend

Aug15

Aug16

Aug17

Aug18

Aug19

Aug20

Aug21

Aug22

Aug23

Cash-to-Debt

Get a 7-Day Free Trial

No Debt

Algernon Pharmaceuticals Quarterly Data
	Feb19	May19	Aug19	Nov19	Feb20	May20	Aug20	Nov20	Feb21	May21	Aug21	Nov21	Feb22	May22	Aug22	Nov22	Feb23	May23	Aug23	Nov23
Cash-to-Debt	Get a 7-Day Free Trial															No Debt	No Debt	No Debt	No Debt	No Debt

Competitive Comparison

For the Biotechnology subindustry, Algernon Pharmaceuticals's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Algernon Pharmaceuticals Cash-to-Debt Distribution

For the Biotechnology industry and Healthcare sector, Algernon Pharmaceuticals's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where Algernon Pharmaceuticals's Cash-to-Debt falls into.

Algernon Pharmaceuticals Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

Algernon Pharmaceuticals's Cash to Debt Ratio for the fiscal year that ended in Aug. 2023 is calculated as:

Algernon Pharmaceuticals had no debt ⁽¹⁾.

Algernon Pharmaceuticals's Cash to Debt Ratio for the quarter that ended in Nov. 2023 is calculated as:

Algernon Pharmaceuticals had no debt ⁽¹⁾.

Algernon Pharmaceuticals (XCNQ:AGN) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.

Algernon Pharmaceuticals Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of Algernon Pharmaceuticals's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Algernon Pharmaceuticals (XCNQ:AGN) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Algernon Pharmaceuticals Inc (XCNQ:AGN) » Definitions » Cash-to-Debt

Comparable Companies

Traded in Other Exchanges

AGNPF:USA AGW0:Germany

Address

601 West Broadway, Suite 400, Vancouver, BC, CAN, V5Z 4C2

Website

https://www.algernonpharmaceuticals.com

Algernon Pharmaceuticals Inc is a clinical-stage drug development company focused on the disease areas of stroke, idiopathic pulmonary fibrosis and chronic cough. The company's business model is capital efficient and strives to deliver maximum shareholder value. Algernon's approach to drug discovery is based on the concept of drug repurposing. It operates in two reportable segments: the development of repurposed therapeutic drugs in Canada, and the facilitation of the Company's drug candidates into off-label phase II clinical trials (humans) in Australia.

Algernon Pharmaceuticals (XCNQ:AGN) Headlines

No Headlines